官方服务：
资源简介：
To described the effects of BTK inhibitors on CART19
应用场景：
创建时间：
2023-03-16
相关数据集
Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton’s Tyrosine Kinase
Although Bruton’s tyrosine kinase (BTK) has been recognized as a validated drug target for the treatment of B-cell malignances, the emergence of clinical resistance to the first-generation covalent BT
NIAID Data Ecosystem80
North America Bruton Tyrosine Kinase (BTK) Inhibitors Market
The North America Bruton Tyrosine Kinase (BTK) Inhibitors report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insight
IMR REPORTS50
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8-dihydropteridine-6,7-dione
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8-dihydropteridine-6,7-dione Descriptor: 1,2-ETHANEDIOL, 8-(2,3-dihydro-1H-in
Protein Data Bank Japan2023-10-11 更新30
Supplementary Table 2 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
Supplemental Table2. Tracking the evolution of ibrutinib resistance phenotypes, relates to Fig. 2
Figshare2021-11-01 更新60
Discovery of 1‑Amino‑1H‑imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors
Bruton’s tyrosine kinase (BTK) inhibitors suppressing the aberrant activation of BTK have led to a paradigm shift in the therapy of B-cell malignancies. However, there is an urgent need to discover mo
Figshare2021-10-21 更新40
